GLP-1 receptor agonists + SGLT2 inhibitors

Papers on GLP-1 receptor agonists + SGLT2 inhibitors

37 papers10 new in 30 days

Saturday, November 7

AHA Scientific Sessions 2026 Abstract

Diabetes drug combination linked to fewer limb complications

Combined use was linked to a lower rate of major limb complications over time than use of neither class, with a hazard ratio of 0.50.Combined use was linked to a lower rate of major limb complications over time than use of neither class, with a hazard ratio of 0.50.

A dark blue-green leg with an intact foot and visible artery contrasts with a smaller gray leg with foot damage, beside groups of faceless people.
Cohort · 13,471 peopleType 2 diabetes

Tuesday, November 3

Monday, November 2

Sunday, November 1

Saturday, October 31

Friday, October 23

Research Square

Combined diabetes drugs linked to fewer limb events and deaths

Combined use was associated with lower relative rates of serious limb complications and death than neither drug type, with hazard ratios of 0.50 and 0.23.Combined use was associated with lower relative rates of serious limb complications and death than neither drug type, with hazard ratios of 0.50 and 0.23.

Flowchart of Cohort Selection for the GLP1-RA/SGLT2i Exposure Analysis
Preprint: cohort · 13,471 peopleDiabetes mellitus

Thursday, September 17

Friday, September 11

Tuesday, September 1

Wednesday, August 26

Wednesday, August 19

Monday, August 17

Saturday, August 15

Friday, June 5

Tuesday, April 14

Monday, March 2

Monday, February 23

Wednesday, February 18

Friday, January 23

Tuesday, January 13

Monday, November 3